• This is a political forum that is non-biased/non-partisan and treats every person's position on topics equally. This debate forum is not aligned to any political party. In today's politics, many ideas are split between and even within all the political parties. Often we find ourselves agreeing on one platform but some topics break our mold. We are here to discuss them in a civil political debate. If this is your first visit to our political forums, be sure to check out the RULES. Registering for debate politics is necessary before posting. Register today to participate - it's free!

Hydroxychloroquine and Chloroquine for Thousands in New York (5 Viewers)

Jack Hays said:
Nope. Never posted before, and the link in #1,692 was to a paper from late September. In your eagerness to insult, you lose track of the facts,
Click to expand...
You definitely posted the Henry Ford thing before, and the September paper is a non reviewed meta analysis, which is worthless, but you have no clue why because...

you literally have no idea what you’re talking about.
 
Threegoofs said:
You definitely posted the Henry Ford thing before, and the September paper is a non reviewed meta analysis, which is worthless, but you have no clue why because...

you literally have no idea what you’re talking about.
Click to expand...
You are correct. Once in August.
As for the September paper, I'm sure the authors from UCLA, Baylor, Yale and Henry Ford Hospital would challenge your "worthless" characterization.
The larger conclusion, of course, is that the mere existence of the paper (not to mention its positive outcome) makes my point and refutes yours. Research continues.
 
Early Treatment Saves Lives
Click to expand...
https://aapsonline.org/early-treatment-saves-lives/

Association of American Physicians and Surgeons (AAPS)

November 10, 2020

1606199233879.png

The NIH dangerously, and contrary to evidence, recommends no treatment for COVID-19 unless a patient is hospitalized and in need of oxygen. But thankfully, a growing number of courageous physicians across America and around the world are stepping up to put patients first by offering early treatment in order to reduce hospitalizations and save lives.

One helpful development this week is that the peer-reviewed journal the International Journal of Antimicrobial Agents published the pioneering work of Dr. Vladimir Zelenko that found early treatment decreased hospitalizations by 84% and resulted in a 5-fold reduction in death.

AAPS continues advocacy for patient access to treatment as well. Thursday of this week, the AAPS Doctors Are In webinar series was honored to feature one of the leaders in this movement to encourage ambulatory treatment, Peter McCullough, MD.

Dr. McCullough presented the rationale behind early treatment and peer-reviewed protocols that can be implemented immediately to manage COVID-19 patients at home.
Click link above for full article.
Click to expand...
The article provide a link to Dr. Vladimir Zelenko clinical trial study with hydroxychloroquine with and azithromycin, which found that early treatment decreased hospitalizations by 84% and resulted in a 5-fold reduction in death.

Highlights of the study:

First COVID-19 outpatient study based on risk stratification and early antiviral treatment at the beginning of the disease.

Low-dose hydroxychloroquine combined with zinc and azithromycin was an effective therapeutic approach against COVID-19.

Significantly reduced hospitalization rates in the treatment group.

Reduced mortality rates in the treatment group.
 
Sandokan said:
The article provide a link to Dr. Vladimir Zelenko clinical trial study with hydroxychloroquine with and azithromycin, which found that early treatment decreased hospitalizations by 84% and resulted in a 5-fold reduction in death.

Highlights of the study:

First COVID-19 outpatient study based on risk stratification and early antiviral treatment at the beginning of the disease.

Low-dose hydroxychloroquine combined with zinc and azithromycin was an effective therapeutic approach against COVID-19.

Significantly reduced hospitalization rates in the treatment group.

Reduced mortality rates in the treatment group.
Click to expand...

Get a clue, dude.

mediabiasfactcheck.com

Association of American Physicians and Surgeons (AAPS) - Bias and Credibility

QUESTIONABLE SOURCE A questionable source exhibits one or more of the following: extreme bias, consistent promotion of propaganda/conspiracies, poor or no
mediabiasfactcheck.com mediabiasfactcheck.com

Overall, we rate the Association of American Physicians and Surgeons (AAPS) an extreme right Questionable source based on the promotion of quackery level pseudoscience, conspiracy theories, use of poor sources, a lack of transparency with funding as well as numerous false claims and failed fact checks.
 
I got my covid shield, now I can go anywhere without a mask!

20201124_084850.jpg
 
Sandokan said:
The article provide a link to Dr. Vladimir Zelenko clinical trial study with hydroxychloroquine with and azithromycin, which found that early treatment decreased hospitalizations by 84% and resulted in a 5-fold reduction in death.

Highlights of the study:

First COVID-19 outpatient study based on risk stratification and early antiviral treatment at the beginning of the disease.

Low-dose hydroxychloroquine combined with zinc and azithromycin was an effective therapeutic approach against COVID-19.

Significantly reduced hospitalization rates in the treatment group.

Reduced mortality rates in the treatment group.
Click to expand...
Sandokan said:
The article provide a link to Dr. Vladimir Zelenko clinical trial study with hydroxychloroquine with and azithromycin, which found that early treatment decreased hospitalizations by 84% and resulted in a 5-fold reduction in death.

Highlights of the study:

First COVID-19 outpatient study based on risk stratification and early antiviral treatment at the beginning of the disease.

Low-dose hydroxychloroquine combined with zinc and azithromycin was an effective therapeutic approach against COVID-19.

Significantly reduced hospitalization rates in the treatment group.

Reduced mortality rates in the treatment group.
Click to expand...
Are you confusing the Association of American Physicians (a politically biased group that frequently pedals conspiracy theories and is more about devisive politics than medicine) with the American College of Physicians that is dedicated to improving medical care?
 
year2late said:
Are you confusing the Association of American Physicians (a politically biased group that frequently pedals conspiracy theories and is more about devisive politics than medicine) with the American College of Physicians that is dedicated to improving medical care?
Click to expand...
They are literally the medical arm of Zerohedge
 
Hydroxychloroquine does not benefit adults hospitalized with ...
www.nih.gov › news-events › news-releases › hydroxy...
Nov 9, 2020 — A National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults with ...
https://www.nejm.org/doi/full/10.1056/NEJMe2020388


Effect of pre-exposure use of hydroxychloroquine on COVID ...
www.thelancet.com › PIIS2665-9913(20)30378-7 › fulltext
Nov 5, 2020 — Between Sept 1, 2019, and March 1, 2020, of 194 637 people with rheumatoid arthritis or systemic lupus erythematosus, 30 569 (15·7%) received ...
by CT Rentsch · ‎Cited by 1
‎Introduction · ‎Methods · ‎Discussion · ‎References
 
Jack Hays said:
Hydroxychloroquine does not benefit adults hospitalized with ...
www.nih.gov › news-events › news-releases › hydroxy...
Nov 9, 2020 — A National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults with ...
https://www.nejm.org/doi/full/10.1056/NEJMe2020388

Effect of pre-exposure use of hydroxychloroquine on COVID ...
www.thelancet.com › PIIS2665-9913(20)30378-7 › fulltext
Nov 5, 2020 — Between Sept 1, 2019, and March 1, 2020, of 194 637 people with rheumatoid arthritis or systemic lupus erythematosus, 30 569 (15·7%) received ...
by CT Rentsch · ‎Cited by 1
‎Introduction · ‎Methods · ‎Discussion · ‎References
Click to expand...
Why are you still beating this dead horse?
 
All these medical studies of early treatments of coronavirus patients with hydroxychloroquine show that it decreased hospitalizations and cut death rates.

June 25, 2020
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315163/

July 02, 2020
Treatment with Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients, Henry Ford Health System Study Shows
https://www.henryford.com/news/2020/07/hydro-treatment-study

September 2, 2020
Studies in Italy Offer New Evidence of HCQ Role in Saving Lives
https://yated.com/studies-in-italy-offer-new-evidence-of-hcq-role-in-saving-lives/

September 13, 2020
Sulaiman T, Mohana A, Alawdah L, et al. The effect of early hydroxychloroquine-based therapy in COVID-19 patients in ambulatory care settings: A nationwide prospective cohort study. Preprints September 13, 2020. https://doi.org/10.1101/2020.09.09.20184143

October 26, 2020
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study
https://www.sciencedirect.com/science/article/pii/S0924857920304258?via=ihub
 
Sandokan said:
All these medical studies of early treatments of coronavirus patients with hydroxychloroquine show that it decreased hospitalizations and cut death rates.

June 25, 2020
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315163/

July 02, 2020
Treatment with Hydroxychloroquine Cut Death Rate Significantly in COVID-19 Patients, Henry Ford Health System Study Shows
https://www.henryford.com/news/2020/07/hydro-treatment-study

September 2, 2020
Studies in Italy Offer New Evidence of HCQ Role in Saving Lives
https://yated.com/studies-in-italy-offer-new-evidence-of-hcq-role-in-saving-lives/

September 13, 2020
Sulaiman T, Mohana A, Alawdah L, et al. The effect of early hydroxychloroquine-based therapy in COVID-19 patients in ambulatory care settings: A nationwide prospective cohort study. Preprints September 13, 2020. https://doi.org/10.1101/2020.09.09.20184143

October 26, 2020
COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study
https://www.sciencedirect.com/science/article/pii/S0924857920304258?via=ihub
Click to expand...
You forgot the latest RCT failure.

But then again, those studies don’t appear on your wingnut sites.
 
Statement of Harvey A. Risch, MD, PhD

Professor of Epidemiology, Yale School of Public Health
Click to expand...
https://www.hsgac.senate.gov/imo/media/doc/Testimony-Risch-2020-11-19.pdf

Senators and colleagues: thank you for convening this hearing. We all understand the endemic disease that we are facing, that we have to face it head-on and not hide from it hoping that it will go away. I want to give you my perspective....

About studies of hydroxychloroquine early use in high-risk outpatients, every one of them, and there are now seven studies, has shown significant benefit: 636 outpatients in São Paulo, Brazil; 199 clinic patients in Marseille, France; 717 patients across a large HMO network in Brazil; 226 nursing-home patients in Marseille; 1,247 outpatients in New Jersey; 100 long-term care institution patients in Andorra (between France and Spain); and 7,892 patients across Saudi Arabia. All these studies pertain to the early treatment of high-risk outpatients—and all showed about 50 percent or greater reductions in hospitalization or death. The Saudi study was a national study and showed 5-fold reduction in mortality for hydroxychloroquine plus zinc vs zinc alone. Not a single fatal cardiac arrhythmia was reported among these thousands of patients attributable to the hydroxychloroquine. These are the non-randomized but controlled trials that have been published....

This body of evidence dramatically outweighs the risk/benefit evidence for remdesivir, monoclonal antibodies or the difficult to use bamlanivimab that the FDA has approved for emergency use authorizations while denying the emergency use authorization for hydroxychloroquine. This egregious double standard for hydroxychloroquine needs to be overturned immediately and its emergency use authorization application approved. This is how we will get on the road to early outpatient treatment and the major curtailment of mortality. Thank you.
Click link above for full article.
Click to expand...
All these studies referenced by Dr. Risch, have shown that coronavirus patients treated with hydroxychloroquine-based therapy had positives outcomes, prevent hospitalization and mortality. Physicians, clinics, facilities, and health systems to reduce COVID-19 hospitalizations and deaths, shall be allow to use hydroxychloroquine. Treatment of coronavirus should be based on physician judgment considering the benefits and risks of treatment. Have been demonstrated that early treatment with hydroxychloroquine save lives.
 
Video of Dr. of Harvey A. Risch at the Senate hearing about Covid-19 treatment with hydroxychloroquine.

Dr. Risch gave a heroic testimony at the Senate hearing. Dr. Risch quote: “This egregious double standard for hydroxychloroquine needs to be overturned immediately and its emergency use authorization application approved. This is how we will get on the road to early outpatient treatment and the major curtailment of mortality.”

This Cicero quote addressing the Roman Senate, come very handy in this particular case that Dr. Risch is addressing the U.S. Senate: "A nation can survive its fools, and even the ambitious. But it cannot survive treason from within. An enemy at the gates is less formidable, for he is known and carries his banners openly.”
 
Threegoofs said:
It’s all wingnut ‘research’.
Click to expand...
Professor Risch disagrees.
". . . As I have said on many occasions, the evidence for benefit of hydroxychloroquine used early in high-risk outpatients is extremely strong, and the evidence against harm is also equally strong. This body of evidence dramatically outweighs the risk/benefit evidence for remdesivir, monoclonal antibodies or the difficult to use bamlanivimab that the FDA has approved for emergency use authorizations while denying the emergency use authorization for hydroxychloroquine. This egregious double standard for hydroxychloroquine needs to be overturned immediately and its emergency use authorization application approved. This is how we will get on the road to early outpatient treatment and the major curtailment of mortality. Thank you."
 
Jack Hays said:
Professor Risch disagrees.
". . . As I have said on many occasions, the evidence for benefit of hydroxychloroquine used early in high-risk outpatients is extremely strong, and the evidence against harm is also equally strong. This body of evidence dramatically outweighs the risk/benefit evidence for remdesivir, monoclonal antibodies or the difficult to use bamlanivimab that the FDA has approved for emergency use authorizations while denying the emergency use authorization for hydroxychloroquine. This egregious double standard for hydroxychloroquine needs to be overturned immediately and its emergency use authorization application approved. This is how we will get on the road to early outpatient treatment and the major curtailment of mortality. Thank you."
Click to expand...
He’s an outlier. A wingnut. And his area is oncology, not infectious disease.

If I really, really believe dogshit capsules are the best treatment for COVID, do you also advocate that I be given lots of funding to research my idea?
 
Threegoofs said:
He’s an outlier. A wingnut. And his area is oncology, not infectious disease.

If I really, really believe dogshit capsules are the best treatment for COVID, do you also advocate that I be given lots of funding to research my idea?
Click to expand...
Your claim is incorrect.
Harvey A. Risch, MD, PhD, Professor of Epidemiology, Yale School of Public Health
 
You must log in or register to reply here.

Users who are viewing this thread

Total: 6 (members: 0, guests: 6)
Back
Top Bottom